Award
NIH Reporter #PAR-24-049
EPIC-LT: Eliminating PGD through Inhibition of CCR5 in Lung Transplantation
Recipient
University of California, San Francisco
Award Amount
$246,725.00
Ceiling
$246,725.00
Awarded
August 21, 2026
Identifier
PAR-24-049
NIH grant awarded by NHLBI to UCSF for a clinical trial targeting primary graft dysfunction in lung transplantation through CCR5 inhibition, including pilot studies and biomarker development.
Description
This is a NIH grant opportunity for a clinical trial focusing on lung transplantation, specifically targeting primary graft dysfunction (PGD) through CCR5 inhibition. The project involves pilot studies, safety assessments, and development of biomarkers for future multicenter trials. The award is managed by the NHLBI and involves collaboration with UCSF. The project aims to inform a larger future clinical trial and develop assays for subphenotyping in lung transplant recipients.